News | January 22, 2013

Treatment Chair Developed By Procure Improves Patient Comfort, Increases Efficiency of Care

Device allows patients to sit up during cancer treatments

An innovative modification of a treatment chair used with cancer patients allows those who have problems lying down during procedures to sit upright, providing greater comfort. The modified chair was developed to be used for proton therapy but can also be used in conventional radiation therapy, providing the chair can be attached to a robotic positioner.   

Engineers at ProCure Treatment Centers, Inc. (ProCure), which develops and operates a network of proton centers in the U.S., developed an intra-cranial chair to address the difficulty some patients have when they need to lie flat for treatment. The chair also gives proton centers the option of using less expensive beam delivery systems rather than large gantry systems, the industry standard for treating these cases, as it was designed with multiple rotation points that complement the limited beam angles offered by the inclined or fixed beam systems. ProCure also developed the inclined beam technology, which can be used to treat approximately 80 percent of tumors that normally require the use of a gantry, but in a space about half the size.
“Some patients, especially those with head and neck tumors, have difficulty swallowing while lying on a standard treatment table,” said Eugen Hug, M.D., ProCure medical director and chief medical officer. “Not only is this device helpful in greatly enhancing patient comfort but it improves patient flow by allowing us to use the inclined beam system for more people.” 
The intra-cranial chair is in use at ProCure’s Oklahoma and Illinois centers and is now commercially available to other proton centers, hospitals and radiation oncology practices.
 
“Our sole focus is providing exceptional patient care and we continue to do that by developing new innovations that place our patient’s comfort front and center,” said Niek Schreuder, senior vice president of medical physics and technology at ProCure. “Our engineers at the ProCure Training and Development Center strive to bring new and improved technology to cancer therapy, not only for our center but for all practices that are treating patients who could benefit.”
 
Proton therapy is an advanced form of radiation and an important alternative to standard X-ray radiation for many patients with cancer and for some noncancerous tumors. Proton therapy has been shown to be beneficial in the treatment of a broad range of tumor types including brain, central nervous system, gastrointestinal, head and neck, lung and prostate as well as sarcomas and many pediatric cancers. The precision of proton therapy makes it especially effective for treating children and adults with anatomically complex tumors such as base of skull and tumors along the spinal cord.
 
For more information: www.ProCure.com
 

Related Content

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | March 19, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group

Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group. Racial/ethnic groups are mutually exclusive. Data for the non‐Hispanic American Indian/Alaska Native (AI/AN) population are restricted to Indian Health Service Purchased/Referred Care Delivery Area (PRCDA) counties. API indicates Asian/Pacific Islander. Chart courtesy of ACS Journals 

News | Radiation Oncology | March 16, 2020
March 16, 2020 — The Ann...
Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy